{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:50:59Z","timestamp":1791402659683,"version":"4.3.3"},"reference-count":68,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The Myasthenia Gravis Activities of Living (MG\u2010ADL) scale is an 8\u2010item patient\u2010reported scale that measures myasthenia gravis (MG) symptoms and functional status. The objective of the current review is to summarize the psychometric properties of the MG\u2010ADL and published evidence of MG\u2010ADL use. A targeted literature review for published studies of the MG\u2010ADL was conducted using a database and gray literature search. A total of 48 publications and 35 clinical trials were included. Studies indicated that the MG\u2010ADL is a reliable and valid measure that has been used as an outcome in clinical trials and observational studies to measure MG symptoms and response to treatment. While most often used as a secondary endpoint in clinical trials, its use as a primary endpoint has increased in recent years. The most common MG\u2010ADL endpoint is change in MG\u2010ADL score from baseline, although there has been an increase in the analysis of a responder threshold using the MG\u2010ADL. A new concept of minimal symptom expression (MSE) has emerged more recently. Duration of treatment effect is another important construct that is being increasingly evaluated using the MG\u2010ADL. The use of the MG\u2010ADL as a primary endpoint in clinical trials and in responder threshold analyses to indicate treatment improvement has increased in recent years. MSE using the MG\u2010ADL shows promise in helping to determine success of treatment and may be the aspirational goal of MG treatment for the future once validated, particularly given the evolving treatment landscape in MG.<\/jats:p>","DOI":"10.1002\/mus.27476","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T05:21:04Z","timestamp":1641446464000},"page":"630-639","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["Utilization of MG\u2010ADL in myasthenia gravis clinical research and care"],"prefix":"10.1002","volume":"65","author":[{"given":"Srikanth","family":"Muppidi","sequence":"first","affiliation":[{"name":"Neurology &amp; Neurological Sciences Stanford University School of Medicine Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Silvestri","sequence":"additional","affiliation":[{"name":"Department of Neurology State University of New York, Buffalo Jacobs School of Medicine and Biomedical Sciences Buffalo New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Tan","sequence":"additional","affiliation":[{"name":"Xcenda LLC Carrollton Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Riggs","sequence":"additional","affiliation":[{"name":"Xcenda LLC Carrollton Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Leighton","sequence":"additional","affiliation":[{"name":"Formerly of Argenx BVBA Zwijnaarde Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn A.","family":"Phillips","sequence":"additional","affiliation":[{"name":"Argenx US Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,1,6]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29894"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70063-8"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/85520"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21713"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.006"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb11015.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.10.1316"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198703193161205"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1487"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26435"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-200484"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25764"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-017-3083-6"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pjnns.2017.12.012"},{"issue":"1","key":"e_1_2_9_16_1","first-page":"33","article-title":"Validation study of the Malay version of the myasthenia gravis quality of life (MGQOL)15 and myasthenia gravis activities of daily living (MGADL) questionnaires","volume":"21","author":"Thabit AAM","year":"2016","journal-title":"Neurol Asia"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2017.05.021"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09770-y"},{"key":"e_1_2_9_20_1","unstructured":"Blue Cross Blue Shield of Massachusetts. Pharmacy Medical Policy: Soliris Ultomiris and Neuromyelitis Optica Policy Updated August 2021. Accessed November 30 2021.https:\/\/www.bluecrossma.org\/medical-policies\/sites\/g\/files\/csphws2091\/files\/acquiadam-assets\/093%20Soliris%20Ultomiris%20and%20Neuromyelitis%20Optica%20Policy.pdf"},{"key":"e_1_2_9_21_1","unstructured":"Magellan Rx Management. SOLIRIS (eculizumab) Prior Authorization Criteria Updated September 1 2020; Accessed November 30 2021.https:\/\/specialtydrug.magellanprovider.com\/media\/233203\/mh_mrx_soliris_09_20.pdf"},{"key":"e_1_2_9_22_1","unstructured":"United Healthcare. Complement Inhibitors (Soliris & Ultomiris). 2021.https:\/\/www.uhcprovider.com\/content\/dam\/provider\/docs\/public\/policies\/comm-medical-drug\/complement-inhibitors.pdf"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22140"},{"issue":"1","key":"e_1_2_9_24_1","first-page":"56","article-title":"Hope, coping, and quality of life in adults with myasthenia gravis","volume":"38","author":"Koopman WJ","year":"2016","journal-title":"Can J Neurosci Nurs"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21142"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25948"},{"key":"e_1_2_9_27_1","first-page":"498","article-title":"Correlation of neuro\u2010QOL with MG\u2010ADL, QMG, and MG\u2010QOL15 in assessing the spectrum of disease in patients with refractory generalised myasthenia gravis in the REGAIN study","volume":"24","author":"Andersen H","year":"2017","journal-title":"Eur J Neurol"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004676"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25381"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21053"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21880"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000431284"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26910"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26313"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.50901"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02148-2"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.538"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159993"},{"issue":"15","key":"e_1_2_9_39_1","doi-asserted-by":"crossref","first-page":"S43.001","DOI":"10.1212\/WNL.92.15_supplement.S43.001","article-title":"Proof\u2010of\u2010concept and safety of the anti\u2010FcRn antibody rozanolixizumab in patients with moderate\u2010to\u2010severe generalized myasthenia gravis (GMG): a phase 2a study","volume":"92","author":"Bril V","year":"2019","journal-title":"Neurology"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190464"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005323"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23839"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.05.004"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1159\/000502818"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.11.009"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2017.08.014"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26790"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2006.07.006"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26447"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.47.0513"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002795"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000312374.95186.cc"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116740"},{"issue":"20","key":"e_1_2_9_55_1","first-page":"2006","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe GI","year":"2016","journal-title":"N Engl J Med"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-300148"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2010.12.012"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617721092"},{"key":"e_1_2_9_59_1","unstructured":"Alexion Pharmaceuticals. Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study). 2019; Accessed May 5 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01997229"},{"key":"e_1_2_9_60_1","unstructured":"Food and Drug Administration.Food and Drug Administration. Plan for Issuance of Patient\u2010Focused Drug Development Guidance: Under 21st Century Cures Act Title III Section 3002.2017; Accessed May 14 2021https:\/\/www.fda.gov\/media\/105979\/download"},{"key":"e_1_2_9_61_1","unstructured":"argenx. An Efficacy and Safety Study of ARGX\u2010113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness (ADAPT). 2021; Accessed May 5 2021https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03669588."},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06817.x"},{"key":"e_1_2_9_63_1","unstructured":"UCB Biopharma SRL. A Study to Investigate the Long\u2010Term Safety Tolerability and Efficacy of Rozanolixizumab in Adult Patients with Generalized Myasthenia Gravis. 2021; Accessed May 5 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04124965."},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.5125"},{"issue":"15","key":"e_1_2_9_65_1","doi-asserted-by":"crossref","first-page":"P5.4\u2010039","DOI":"10.1212\/WNL.92.15_supplement.P5.4-039","article-title":"Retrospective longitudinal assessment of mg\u2010adl score with treatment of myasthenia gravis","volume":"92","author":"Varon M","year":"2019","journal-title":"Neurology"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.1.16"},{"key":"e_1_2_9_67_1","first-page":"S18","article-title":"When is better good enough? Patient acceptable states in myasthenia gravis","volume":"58","author":"Barnett C","year":"2018","journal-title":"Muscle Nerve"},{"key":"e_1_2_9_68_1","unstructured":"European Medicines Agency. European Public Assessment Report: Soliris (eculizumab). Updated October 30 2019.2019; Accessed February 18 2021 https:\/\/www.ema.europa.eu\/en\/documents\/overview\/soliris-epar-medicine-overview_en.pdf"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000156"}],"container-title":["Muscle &amp; Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.27476","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mus.27476","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.27476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T16:20:24Z","timestamp":1726417224000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.27476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,6]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1002\/mus.27476"],"URL":"https:\/\/doi.org\/10.1002\/mus.27476","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"value":"0148-639X","type":"print"},{"value":"1097-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,6]]},"assertion":[{"value":"2021-06-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}